Nitrostat Shortage: What Providers and Prescribers Need to Know in 2026

As clinicians managing patients with coronary artery disease, you are likely familiar with patients calling to report that their pharmacy doesn't have Nitrostat in stock. While nitroglycerin sublingual tablets are not currently in a declared national shortage as of 2026, localized supply gaps continue to create real-world access challenges — particularly for patients prescribed the 0.3 mg or 0.6 mg strengths.

This guide provides a clinical overview of the current availability situation, therapeutic alternatives, formulary considerations, and patient counseling strategies for 2026.

Current Supply Status: What the Data Shows

The FDA Drug Shortage Database does not currently list nitroglycerin sublingual tablets (Nitrostat or generic) as a national shortage. Multiple manufacturers hold ANDA approvals for generic nitroglycerin sublingual tablets, providing market redundancy that has historically prevented sustained national shortages of this formulation.

However, several clinical considerations apply:

The 0.4 mg strength (bottles of 25 and 100) is far more commonly stocked than 0.3 mg or 0.6 mg. Patients prescribed non-standard strengths have more difficulty filling prescriptions.

Nitroglycerin IV formulations and ointment (Nitro-Bid) have experienced more significant shortages in recent years than sublingual tablets.

Regional distributor disruptions can temporarily deplete pharmacy stock across multiple chains simultaneously, creating area-wide shortages that don't appear in national data.

Therapeutic Alternatives: Clinical Considerations

When sublingual nitroglycerin tablets are unavailable, the following alternatives merit consideration based on clinical context:

Nitroglycerin lingual spray (Nitrolingual Pumpspray, NitroMist): Preferred substitution for acute rescue. Same pharmacodynamics as sublingual tablets; comparable onset of 1–3 minutes. Bioavailability may be slightly higher due to buccal absorption without first-pass metabolism. Each spray delivers 0.4 mg nitroglycerin; 1–2 sprays per episode, may repeat every 5 minutes up to 3 doses. Longer shelf life than sublingual tablets after opening.

Sublingual isosorbide dinitrate (5 mg): Slower onset than sublingual nitroglycerin (requires hepatic conversion to the active mononitrate metabolite) but longer duration of action (4–6 hours). Can serve as a bridge therapy for patients who need a sublingual option but cannot access nitroglycerin tablets.

Isosorbide mononitrate (oral): Appropriate substitution for patients using Nitrostat prophylactically (patches or long-acting prevention) rather than for acute rescue. Not appropriate as a standalone rescue medication.

Prescribing Considerations for Common Shortage Scenarios

Scenario 1: Patient uses Nitrostat as rescue medication only.

Prescribe nitroglycerin 0.4 mg lingual spray as a bridge. 1–2 sprays every 5 minutes, up to 3 doses; if pain persists, follow standard ACS protocol and call emergency services.

Scenario 2: Patient takes Nitrostat prophylactically before exertion.

Nitroglycerin spray can serve as a direct substitute. Alternatively, consider optimizing daily anti-anginal therapy with isosorbide mononitrate or beta-blocker titration to reduce the need for situational rescue dosing.

Scenario 3: Patient requires a specific non-0.4 mg strength.

Consider whether the 0.4 mg strength is clinically appropriate. In many patients, dose adjustment is possible with physician oversight. If the specific strength is medically necessary, work with the pharmacy to place a special order from the distributor or identify a compounding pharmacy as a last resort.

Patient Safety Counseling Points

When counseling patients about Nitrostat access, reinforce the following:

Replace any open Nitrostat bottle at 6 months, regardless of remaining tablets — potency degrades with time and exposure to heat, light, or moisture.

Store in the original glass container at room temperature (68–77°F); avoid pillboxes, which are not appropriate containers for nitroglycerin tablets.

Do not share Nitrostat with other household members — dosing is prescribed specifically and mixing with PDE-5 inhibitors is contraindicated and potentially fatal.

Call 911 if chest pain persists after 3 doses in 15 minutes — do not continue self-medicating.

How medfinder Can Help Your Patients

medfinder is a service that calls pharmacies near your patient to identify which ones can fill their prescription. This is particularly useful when patients report difficulty finding their medication — instead of spending time on hold with multiple pharmacies, your care team can direct patients to medfinder.com/providers for rapid pharmacy location support.

See also: How to help your patients find Nitrostat in stock: A provider's guide.